OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
HANN56

Hannah Joseph Hospital Ltd

Healthcare Facilities & ServicesVerified

Hannah Joseph Hospital Ltd maintains a debt-to-equity ratio of 0.71, indicating a moderate reliance on debt financing, while its current ratio of 1.47 suggests adequate short-term liquidity to cover obligations. The company's liquidity position is assessed as medium, with free cash flow of INR 23.24 million and operating cash flow of INR 196.02 million, but net cash is negative after subtracting total debt. Profitability metrics show a return on equity (ROE) of 13.88% and a return on assets (ROA) of 7.26%, both exceeding the typical thresholds for healthcare facilities, which are often in the 5-10% range for ROE and 3-6% for ROA. The operating margin of 17.34% (calculated from operating income of INR 134.49 million on revenue of INR 775.31 million) is strong compared to industry medians. The company's revenue is concentrated in India, with no disclosed international operations. Its services span neurology, cardiology, psychiatry, and trauma care, with no material segment disclosures provided. The lack of segment-level revenue data limits visibility into geographic or therapeutic concentration risks. The company's growth trajectory is not explicitly outlined in the input data, but its capital expenditure of INR -121.27 million suggests ongoing investment in infrastructure or expansion. No specific revenue growth rates or outlooks are provided for the current or next fiscal year. Risk factors include a medium liquidity risk due to negative net cash and a moderate debt load. Dilution risk is assessed as low, with no dilution potential identified in the basic shares outstanding. No recent events, such as filings or transcripts, are provided in the input data to inform near-term strategic or operational developments.

30-day price · HANN+7.35 (+10.9%)
Low$67.01High$88.80Close$75.00As of15 May, 00:00 UTC
Profile
CompanyHannah Joseph Hospital Ltd
TickerHANN.BO
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Hannah Joseph Hospital Ltd provides healthcare services in India, focusing on neurology, cardiology, psychiatry, and trauma care, with ultra-modern medical practices and infrastructure.

Classification. The company is classified under the Healthcare economic sector, Healthcare Services & Equipment business sector, and Healthcare Facilities & Services industry, with a confidence level of 0.92.

Hannah Joseph Hospital Ltd maintains a debt-to-equity ratio of 0.71, indicating a moderate reliance on debt financing, while its current ratio of 1.47 suggests adequate short-term liquidity to cover obligations. The company's liquidity position is assessed as medium, with free cash flow of INR 23.24 million and operating cash flow of INR 196.02 million, but net cash is negative after subtracting total debt. Profitability metrics show a return on equity (ROE) of 13.88% and a return on assets (ROA) of 7.26%, both exceeding the typical thresholds for healthcare facilities, which are often in the 5-10% range for ROE and 3-6% for ROA. The operating margin of 17.34% (calculated from operating income of INR 134.49 million on revenue of INR 775.31 million) is strong compared to industry medians. The company's revenue is concentrated in India, with no disclosed international operations. Its services span neurology, cardiology, psychiatry, and trauma care, with no material segment disclosures provided. The lack of segment-level revenue data limits visibility into geographic or therapeutic concentration risks. The company's growth trajectory is not explicitly outlined in the input data, but its capital expenditure of INR -121.27 million suggests ongoing investment in infrastructure or expansion. No specific revenue growth rates or outlooks are provided for the current or next fiscal year. Risk factors include a medium liquidity risk due to negative net cash and a moderate debt load. Dilution risk is assessed as low, with no dilution potential identified in the basic shares outstanding. No recent events, such as filings or transcripts, are provided in the input data to inform near-term strategic or operational developments.
Key takeaways
  • The company maintains a strong ROE of 13.88% and ROA of 7.26%, outperforming typical healthcare facility benchmarks.
  • Liquidity is moderate, with a current ratio of 1.47 and free cash flow of INR 23.24 million, but net cash is negative after subtracting total debt.
  • Debt-to-equity of 0.71 indicates a balanced capital structure, with no immediate dilution risk.
  • Revenue concentration in India and lack of segment-level data limit visibility into geographic and therapeutic diversification.
  • Capital expenditure of INR -121.27 million suggests ongoing investment in infrastructure or expansion.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyINR
Revenue$775.3M
Gross profit$659.8M
Operating income$134.5M
Net income$72.1M
R&D
SG&A
D&A
SBC
Operating cash flow$196.0M
CapEx-$121.3M
Free cash flow$23.2M
Total assets$992.9M
Total liabilities$473.6M
Total equity$519.4M
Cash & equivalents$76.2M
Long-term debt$368.6M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$519.4M
Net cash-$292.4M
Current ratio1.5
Debt/Equity0.7
ROA7.3%
ROE13.9%
Cash conversion2.7%
CapEx/Revenue-15.6%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Biotechnology · cohort 9 companies
MetricHANNActivity
Op margin17.3%11.5% medp25 9.9% · p75 15.0%top quartile
Net margin9.3%8.6% medp25 6.3% · p75 12.4%above median
Gross margin85.1%28.8% medp25 28.8% · p75 28.8%top quartile
CapEx / revenue-15.6%4.2% medp25 3.8% · p75 4.2%bottom quartile
Debt / equity71.0%71.3% medp25 60.7% · p75 71.3%below median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-04 06:59 UTC#b19395a0
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 07:00 UTCJob: 0a7a8536